https://www.selleckchem.com/pr....oducts/srt2104-gsk22
The most common adverse events during induction were anemia (91%), febrile neutropenia (64%; grade 4 in 46%), thrombocytopenia (39%), and mucositis (21%). Peripheral neuropathy was encountered in 7 (12%) patients (grade 3; n=1). Two deaths from septic shock were reported in patients with initial poor performance status. After a median follow-up of 17 months, the 2-year progression-free survival and overall survival rates were 86% and 87%, respectively. The replacement of vindesine with vincristine in mR-ACVBP seems feasible,
Curtir
Comentario
Compartilhar
